CLDX beat EPS expectations by 6.71%
Nov 06, 2024, 11:31 PM
0.00%
What does CLDX do
Celldex Therapeutics, based in Hampton, New Jersey, develops novel therapeutics targeting mast cell-mediated diseases and employs 160 staff. Their pipeline includes Barzolvolimab and the bispecific antibody CDX-585 for inflammatory diseases and oncology.
Celldex Therapeutics (CLDX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Celldex Therapeutics's actual EPS was -$0.64, beating the estimate of -$0.69 per share, resulting in a 6.71% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.